Fig. 6: CR fusion-leukemia is sensitive to HDAC inhibitors.

a Experimental design to determine the effects of HDAC inhibitors on blasts of CRL/N and WT/N mice in vitro. b Colony numbers generated by blasts from CRL/N and WT/N mice with indicated treatments. c The sensitivity of blasts from CRL/N and WT/N mice to HDAC inhibitors. n = 4 independent experiments using blasts from 2 CRL/N and 2 WT/N mice (b, c). d Experimental design to measure the effects of HDAC inhibitors on CRL/N and WT/N mice in vivo. e–f Survival curves of CRL/N mice (e) and WT/N mice (f) administered indicated regents. Three independent experiments were performed, with 3 to 5 mice per group in each experiment (e). Statistical analysis was performed by Log-rank test. g Representative pictures and quantification of spleens of CRL/N and WT/N mice after indicated treatments 20 days post-transplantation. n = 5 mice/group. h–i Frequency of leukemic cells in BM (h) and spleen (i) of CRL/N and WT/N mice administered indicated regents 20 days post-transplantation. CRL/N ATRA treatment, n = 3 mice; other groups, n = 4 mice/group. The data are shown as the mean ± SD, statistical analysis was performed by two-tailed unpaired t test (b–c, g–i). See also Supplementary Fig. 9. Source data are provided as a Source Data file.